Array BioPharma spins off cardiovascular myopathy drug research into new subisidiary
Boulder drug development company Array BioPharma has spun off its research into a treatment for a rare degenerative heart disease into a separate company.
Array BioPharma (Nasdaq: ARRAY), in a filing to the U.S. Securities& Exchange Commission on Chistmas Eve, revealed that it had contributed intellectual property, inventory, equipment, clinical trial data and other material about its experimental cardiomyopathy drug to a subsidiary it ’s calling Yarra Therapeutics.
The oral drug, known only…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Greg Avery Source Type: news
More News: American Health | Cardiology | Cardiomyopathy | Cardiovascular | Clinical Trials | Health Management | Heart | Heart Disease